Sanyou signs two commercial-use licenses for Horizon’s gene-edited CHO-K1 GS knockout cell line, for use in biotherapeutic pipeline development and contract research services
Cambridge, UK, and Shanghai, China, 01 December 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it has granted two commercial licenses for its cGMP-compliant CHOSOURCE™ platform to Sanyou Biopharmaceuticals Co., Ltd. (“Sanyou”), a leading biotechnology company focused on research, development and providing integrated solutions for innovative antibody drug developments. Sanyou will use Horizon’s gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line for the development of pre-clinical antibody drug projects and to support the clinical development and commercialization of its customers’ human biotherapeutic products as well as offering the platform through its contract research services.
“Sanyou is a leading biotechnology company with extensive experience in early stage drug discovery, IND filing and clinical trial management. The Company has established an integrated innovative antibody drug R&D laboratory and we are pleased CHOSOURCE has been selected to support its biotherapeutic pipeline and contract research services offering,” commented Jesús Zurdo, Global Head Bioproduction Business Unit, Horizon Discovery. “Horizon is committed to supporting innovative organizations of all sizes to empower biotherapeutic production using our expression platform. We are proud to have licensed CHOSOURCE to over 80 organizations, from non-for-profit and early stage startups to clinical stage biotechnology and large pharmaceutical companies, and helped enable at least 8 biotherapeutics expressed in these cells to progress into clinical trials.”
Dr. David Lang, CEO, Sanyou Biopharmaceuticals Co., Ltd., said: “Horizon’s CHOSOURCE facilitates the development of stable cell lines for the expression of antibodies and other recombinant proteins, and is recognized in the industry and by regulators for high yield manufacturing. This robust platform will be key in enabling us to generate stable cell lines for the development of antibody drugs, diagnostic products and cell therapy-related components, and allow us to provide a stronger one-stop solution to our clients with IND ready projects through our contract research services and pipeline-enriching collaborations.”
Horizon’s proprietary GS knockout CHO cell line and protocols have a successful track record in the discovery and development of biopharmaceuticals, from transient expression for research applications to the development of stable cell lines for clinical and commercial production of biotherapeutics, including novel multi-specific and complex molecular architectures. The Company licenses its CHOSOURCE expression system to pharmaceutical, biotechnology, and biosimilar companies, as well as contract manufacturing organizations.
For further information on Horizon’s CHO expression system please visit: https://horizondiscovery.com/en/chosource
For high res images please contact email@example.com
|Jesus Zurdo, Global||Dr. David Lang,|
|Head Bioprocessing,||CEO, Sanyou
For further information from Horizon Discovery Group plc, please contact:
Zyme Communications (Trade and Regional Media)
Tel: +44 (0)7811 996 942
For further information from Sanyou Biopharmaceuticals Co., Ltd., please contact:
Strategic Development Department
Tel: +86 400 821 0776
About Horizon Discovery Group plc - horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.
Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.
Horizon’s solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines.
The Company’s customers include many of the world’s foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables the company to focus efforts on development of innovative solutions that not only differentiate the company’s offering, but also fuel development of the next wave of precision medicines.
Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.
About Horizon’s CHOSOURCE™ platform
Horizon’s proprietary CHOSOURCE™ platform, consisting of a GS knockout CHO K1 cell line combined with a dual promoter expression vector, is now established as an industry standard for host cell line development, facilitating cell line selection and optimization of costs and production processes. A comprehensive cell line history and a clear intellectual property position ensure freedom to operate in biotherapeutic production. Horizon’s robust CHO GS knockout host cell line provides an optimal expression system with an excellent performance record.
About Sanyou Biopharmaceuticals Co., Ltd. - sanyoubio.com
Sanyou Biopharmaceuticals is a leading biotechnology company focused on research, development and providing integrated solutions for innovative antibody drug developments. Sanyou is committed to building world-leading antibody drug discovery and development platforms of high-quality, high-throughput, integrated R&D and value transformation. Sanyou is dedicated in constructing a business ecosystem for therapeutic, R&D and diagnostic products and services, and collaborating with global biopharmaceutical, diagnostic, R & D companies to open a new era for the diagnosis and treatment of human diseases.
Since Sanyou’s founding five years ago, Sanyou has been growing rapidly. As of September 2020, Sanyou has a professional team of more than 130 employees, of which more than 70% hold a PhD or Masters degree, and this team is deeply experienced in R&D and industrialization of innovative drugs. Sanyou has established an integrated R&D laboratory of several thousands of square meters with advanced facilities in Caohejing Hi-Tech Park in Shanghai. The laboratory has more than 20 core technology platforms, led by a series of super-trillion phage display antibody libraries, and followed by a full range of essential R&D platforms for innovative antibody drug discovery, antibody engineering, in vitro and in vivo efficacy screening, pharmaceutical properties analysis, cell line construction, and process development.
Sanyou continues to provide new products, services and solutions of "best quality, fastest speed and lowest cost", and examples of innovative solutions including “1-3-9 Systemic Solution for Antibody Drug R&D” and “Integrated Solution for Innovative CART Development”. Sanyou has established friendly business relationships with more than 100 pharmaceutical companies, drug development organizations and diagnostic product development companies around the world.
“Excellence and innovation, pursuit of dreams, striving and evolving, for the benefit of patients”, holding these principles and beliefs, Sanyou looks forward to working with our customers and partners to build a long-term synergistic growth ecosystem and a healthy society.